273 related articles for article (PubMed ID: 31342392)
1. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma.
Thornton MJ; Williamson HV; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Gupta AM; Hyslop T; Hwang ES; Fayanju OM
Ann Surg Oncol; 2019 Oct; 26(10):3166-3177. PubMed ID: 31342392
[TBL] [Abstract][Full Text] [Related]
2. The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma.
Tamirisa N; Williamson HV; Thomas SM; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Hyslop T; Hwang ES; Fayanju OM
J Surg Oncol; 2019 Aug; 120(2):132-141. PubMed ID: 31062375
[TBL] [Abstract][Full Text] [Related]
3. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma.
Loibl S; Volz C; Mau C; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Hanusch C; Jackisch C; Kümmel S; Huober J; Denkert C; Hilfrich J; Konecny GE; Fett W; Stickeler E; Harbeck N; Mehta KM; Nekljudova V; von Minckwitz G; Untch M
Breast Cancer Res Treat; 2014 Feb; 144(1):153-62. PubMed ID: 24504379
[TBL] [Abstract][Full Text] [Related]
4. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
5. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemotherapy and Endocrine Therapy for Older Patients with Estrogen Receptor Positive Breast Cancer: Comparison of Approaches.
Miller KN; Thomas SM; Record SM; Rosenberger LH; DiNome ML; DiLalla G; Force JM; Hwang ES; Plichta JK
Ann Surg Oncol; 2023 Oct; 30(10):6141-6150. PubMed ID: 37466869
[TBL] [Abstract][Full Text] [Related]
8. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
[TBL] [Abstract][Full Text] [Related]
10. Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option?
Özkurt E; Sakai T; Wong SM; Tukenmez M; Golshan M
Ann Surg Oncol; 2019 Oct; 26(10):3260-3268. PubMed ID: 31342356
[TBL] [Abstract][Full Text] [Related]
11. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.
Krug D; Lederer B; Seither F; Nekljudova V; Ataseven B; Blohmer JU; Costa SD; Denkert C; Ditsch N; Gerber B; Hanusch C; Heil J; Hilfrich J; Huober JB; Jackisch C; Kümmel S; Paepke S; Schem C; Schneeweiss A; Untch M; Debus J; von Minckwitz G; Kühn T; Loibl S
Ann Surg Oncol; 2019 Nov; 26(12):3892-3901. PubMed ID: 31350646
[TBL] [Abstract][Full Text] [Related]
12. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
13. Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case-Control Study.
Ryu JM; Park S; Paik HJ; Nam SJ; Kim SW; Lee SK; Yu J; Bae SY; Kim I; Bang SI; Mun GH; Pyon JK; Jeon BJ; Lee JE
Clin Breast Cancer; 2017 Jun; 17(3):204-210. PubMed ID: 28065399
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
[TBL] [Abstract][Full Text] [Related]
15. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma.
Haque W; Arms A; Verma V; Hatch S; Brian Butler E; Teh BS
Breast; 2019 Feb; 43():67-73. PubMed ID: 30496936
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
